Symbiotec Pharmalab

Symbiotec Pharmalab IPO

IPO Open Now

₹14,070

0.47 xOver-subscribed

Bidding Dates 24 Aug, 26 -27 Aug, 26

Min Investment ₹14,070

Lot Size15

Price Range ₹938 – ₹988

Issue Size ₹1,757.30 Cr.

Download Doc

DRHP

IPO Subscription Details

Retail Subscription Details

0.68 x

Non-Institutional Buyers (sHNI)

1 x

Non-Institutional Buyers (bHNI)

0.44 x

Qualified Institutional Buyers (QIB)

0 x

Employees

1.05 x

Total

0.47 x

IPO Timeline

IPO Analysis

Strengths

The company holds a global leadership position with 38.2% market share in corticosteroid and 23.8% in steroidal-hormone APIs in Fiscal 2026, being the only company globally with presence across top 10 APIs in this category.

The company serves over 200 customers across 40+ countries with average relationship tenure of more than 10 years with top customers, demonstrating strong customer stickiness and retention capabilities.

The company operates with 584.67 MT chemical synthesis capacity, 700 KL fermentation capacity, and 20 million vials complex injectables capacity, having completed 108+ inspections without critical observations from global regulators.

Risks

The company derives almost all revenue from API sales (96.07%, 99.10%, and 100.00% in Fiscals 2026, 2025, and 2024 respectively), with top five APIs constituting 62.27%, 63.16%, and 60.37% of revenue. Any reduction in API demand or production disruption could severely impact business operations and financial performance.

The company's manufacturing facilities are subject to periodic inspections by regulatory authorities and customers. Manufacturing or quality control failures may result in regulatory action, reputation damage, and business disruption. Recent US FDA inspections resulted in Form 483 observations requiring responses.

The company generates 67.04%, 55.19%, and 59.97% of revenue from external customers outside India in Fiscals 2026, 2025, and 2024 respectively. The company faces risks from foreign exchange fluctuations, geopolitical tensions, trade restrictions, and varying regulatory requirements across multiple jurisdictions.

Objectives

The company proposes to utilize the net proceeds towards prepayment and/or repayment, in full or in part, of certain outstanding borrowings to reduce overall indebtedness, debt servicing costs, and maintain favorable debt-equity ratio.

The company proposes to utilize the balance net proceeds for general corporate purposes including meeting ongoing contingencies, business requirements, funding growth opportunities, and strategic initiatives as approved by the Board.

Yearly Financial Results

Annual Financials	Mar 2024	Mar 2025	Mar 2026
Revenue	716.25	751.55	869.15
Expenses	590.99	608.85	709.90
Other Income	7.09	4.42	3.11
Total Revenue	723.33	755.98	872.26
Profit Before Tax	130.98	146.97	153.36
Net Profit	100.06	96.79	109.90

Show % Change

Above figures are in Rs. Crores

Balance Sheet

Balance Sheet	Mar 2024	Mar 2025	Mar 2026
Total Assets	1294.79	1579.65	1780.79
Current Assets	508.21	492.86	485.54
Fixed Assets	786.58	1086.79	129.52
Total Equity & Liabilities	1294.79	1579.65	1780.79
Total Liabilities	579.94	764.95	631.20
Current Liabilities	351.21	472.60	527.56
Non Current Liabilities	228.73	292.35	103.64
Total Equity	714.84	814.71	1149.59

Show % Change

Above figures are in Rs. Crores

Cash Flow

Cash Flow	Mar 2024	Mar 2025	Mar 2026
Net Cash Flow	2.94	18.89	-16.35
Investing Activities	-206.41	-306.52	-226.93
Operating Activities	187.50	47.26	174.59
Financing Activities	21.85	278.16	35.99

Show % Change

Above figures are in Rs. Crores

About Symbiotec Pharmalab

Symbiotec Pharmalab Limited is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms: organic chemistry, biotechnology and complex injectables. The company holds a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs) in volume terms, with a global volume market share of 38.2%...more

Website

www.symbiotec.com

Managing DirectorAnil Satwani

About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

Part of Raise Financial Services

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357 Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104